OM
CKPT

Opaleye Management’s Checkpoint Therapeutics CKPT Stock Holding History

Opaleye Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-292,596
Closed -$9.19M – 50
2021
Q1 		$9.19M Buy
+292,596
New +$9.81M 1.35% 21

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Opaleye Management's CKPT Position: Q2 2021 in Review

Opaleye Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 292,596 shares — an estimated $9.19M sold.

Opaleye Management first reported a position in CKPT in Q1 2021 and held it in 1 quarter. The position peaked at $9.19M in Q1 2021. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

  • Opaleye Management reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Opaleye Management sold 292,596 Checkpoint Therapeutics shares in Q2 2021, an estimated $9.19M.
  • Opaleye Management first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 1 quarter.
  • Opaleye Management's Checkpoint Therapeutics position peaked at $9.19M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.